Synjardy is a combination medication containing empagliflozin and metformin. Empagliflozin works by inhibiting SGLT2 in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin decreases hepatic glucose production and improves insulin sensitivity. Together, they help lower blood sugar levels in adults with type 2 diabetes. Synjardy is prescribed to improve glycemic control in conjunction with diet and exercise.